Matrine Sodium Chloride Injection

Pharmacological action: In the liver injury model caused by carbon tetrachloride, this product can reduce the serum transaminase and hydroxyproline content in the liver of animals, alleviate the degree of liver lesions and reduce the serum DHBV-DNA level of ducks infected with hepatitis B virus (HBV).

The main ingredient of this product is matrine, also known as oxymatrine.

This product is a colorless or almost colorless clear liquid.

Used for the treatment of chronic hepatitis B.

Intravenous drip: once a day, 0.4-0.6g each time.

The incidence of adverse reactions is low. Common adverse reactions include dizziness, nausea, vomiting, bitter taste in the mouth, diarrhea, upper abdominal discomfort or pain, and occasionally rash, chest tightness, and fever. Symptoms generally resolve on their own. Some patients may experience redness at the injection site.

1. Patients who are allergic to this product are prohibited from using it. 2. Patients with severe blood, heart, liver, kidney and endocrine diseases are prohibited from using it.

Precautions for children: There is no experience of using the drug in children. Precautions for pregnancy and lactation: Pregnant women should not use it. Use with caution in lactating women.

It has a synergistic effect with central nervous system depressants such as chloral hydrate, an antagonistic effect on central nervous system stimulants such as amphetamine, and can facilitate the convulsive effect of strychnine.

Keep in a sealed container. The validity period is tentatively set at one year.

100ml: 0.6g of oxymatrine (calculated as C15H24N2O2.H2O) and 0.9g of sodium chloride

Tentative 18 months

Yangzhou Zhongbao Pharmaceutical Co., Ltd.

• Founded in:

  1991-11-15

• Address:

  No. 91, Baoying Avenue, New District, Economic Development Zone, Baoying County, Yangzhou City, Jiangsu Province

• Tax NO.:

  91321000608709261R

• Registered Funds:

  60 million yuan

• Website:

  Log in to view

• Email:

  Log in to view